Device Judgement Recommended

Size: px
Start display at page:

Download "Device Judgement Recommended"

Transcription

1 dabl Educational Trust Validation Checklist Device Judgement Recommended Manufacturer IEM Device Stabil O Graph Category Upper Arm (Self) Mode Oscillometric Protocol Reference BHS + ESH Westhoff TH, Schmidt S, Zidek W, van der Giet M. Validation of the Stabil O Graph blood pressure self measurement device Journal of Human Hypertension 2007;22, ,Research Letter Recruitment Screened 112 (BHS), 41 (ESH) Included 85 (BHS), 33 (ESH) Excluded Explained Some Ranges Correct Yes Ages Correct Yes Sexes Correct Yes Description of Methods Good Procedure Description Good Problems Explained Results Description Good Plots Plots are absent from the letter. These were requested and are included below. Result Pass Both BHS and ESH and also on ESH subgroup from BHS sample Signoff Notes Without plots or subsections, the letter format is not an ideal method of prsenting the results but it does benefit from consiseness. Problems with a fall in pressure in the ESH study high range subjects are addressed with a confirmatory analyis using a subset from BHS study subjects. Date 14/5/2008 Plots and were requested from the authors. These and tables from the original manuscript are included below dabl Educational Trust., 34 Main Street, Blackrock, Co. Dublin

2 Tables Table 1A: Number of patients required and number of patients examined in each blood pressure group of the BHS protocol Systolic BP Diastolic BP Minimum Number of Number of (mmhg) (mmhg) number of subjects subjects subjects examined examined required (systolic) (diastolic) < 100 < >180 > Table 1B: Grading criteria of the BHS. To obtain a grade, the device must achieve percentages those reported in the table in all the three categories. Grade Percentage of readings with differences between standard and test device of 5 mmhg 10 mmhg 15 mmhg A 60% 85% 95% B 50% 75% 90% C 40% 65% 85% D Worse than C Worse than C Worse than C 17

3 Table 1C: Results of the BHS validation procedure, n=85 subjects. Numbers in column 1 correspond to number of measurement in the BHS protocol (Device measurements versus preceding and succeding Observer measurements) Mean ± SD of Grade Mean ± SD (mmhg) differences (mmhg) Observer 1 SBP (1 vs 2, 3 vs 4, 5 vs 6) DBP (1 vs 2, 3 vs 4, 5 vs 6) SBP (2 vs 3, 4 vs 5, 6 vs 7) DBP (2 vs 3, 4 vs 5, 6 vs 7) Observer 2 SBP (1 vs 2, 3 vs 4, 5 vs 6) DBP (1 vs 2, 3 vs 4, 5 vs 6) SBP (2 vs 3, 4 vs 5, 6 vs 7) DBP (2 vs 3, 4 vs 5, 6 vs 7) Final grading B 61% 88% 94% 100% ± ± 7.2 A 67% 94% 98% 100% 83.9 ± ± 5.8 A 66% 89% 96% 100% ± ± 6.6 A 67% 95% 99% 100% 83.5 ± ± 5.6 B 61% 88% 93% 100% ± ± 7.3 A 65% 94% 98% 100% 84.0 ± ± 5.8 B 66% 87% 94% 100% ± ± 6.6 A 64% 96% 99% 100% 83.5 ± ± 5.8 SBP A 66% 89% 96% 100% ± ± 6.6 DBP A 65% 94% 98% 100% 84.0 ± ±

4 Table 2A: Number of measurements required and achieved for systolic (SBP) and diastolic (DBP) blood pressure falling in specified error-categories according to phase 1 of the ESH protocol (number of subjects n=15, number of measurements n=45). Error category < 5 mmhg < 10 mmhg < 15 mmhg Required One of Achieved SBP DBP Table 2B: Number of measurements required and achieved for systolic (SBP) and diastolic (DBP) blood pressure falling in specified error-categories according to phase 2.1 of the ESH protocol (number of subjects n=33, number of measurements n=99). Error category < 5 mmhg < 10 mmhg < 15 mmhg Required Two of All of Achieved SBP DBP

5 Table 2C: Number of subjects having the ESH-specified fraction of device-observer differences 5 mmhg for systolic (SBP) and diastolic (DBP) blood pressure (number of subjects 33) Subjects with specified fraction of device-observer differences 2/3 < 5 mmhg 0/3 < 5 mmhg Required Both 22 3 Achieved SBP 25 3 DBP

6 Table 3: Number of subjects obtained for each blood pressure category according to ESH and BHS criteria in the categorization measurement (BPA) and the following validation measurements (BP1 BP7) BPA BP1 BP3 BP5 BP7 ESH Systolic mmhg mmhg mmhg Diastolic mmhg mmhg mmhg BHS Systolic <100 mmhg mmhg mmhg mmhg >180 mmhg Diastolic < 60 mmhg mmhg mmhg mmhg >110 mmhg

7 Figure legends Figure 1: Tukey mean-difference plots (BHS validation process) of systolic (A) and diastolic (B) blood pressure difference of device and observer in 85 subjects (n=255 measurements). Mean difference for systolic blood pressure is -1.9 ± 6.6 mmhg, mean difference for diastolic blood pressure is 0.1 ± 5.8 mmhg. Figure 2: Tukey mean-difference plots (ESH validation process) of systolic (A) and diastolic (B) blood pressure difference of device and observer in 33 subjects (n=99 measurements). Mean device-observer differences were 0.0 ± 5.6 mmhg (systolic) and 1.0 ± 5.7 mmhg (diastolic). 24

8 Figures Figure 1A 25

9 Figure 1B 26

10 Figure 2 Figure 2A Figure 2B 27

Validation Study Result Form

Validation Study Result Form Validation Study Result Form Please complete Section 1 to Section 5 of this form and return it to dabl Educational Trust with copies of the validation Study Ref. plots. In Section 3 to Section 5, complete

More information

Device Equivalence Evaluation Form

Device Equivalence Evaluation Form Comparison of the Omron M6 Comfort IT (HEM-7322U-E) with the Omron M6 Comfort (HEM-7321-E) Devices Omron M6 Comfort IT (HEM-7322U-E) Omron M6 Comfort (HEM-7321-E) Pictures Display Validation ESH 2010 Device

More information

Device Equivalence Evaluation Form

Device Equivalence Evaluation Form Comparison of the HARTMANN Veroval BPU22 with the AViTA BPM63S Devices Item 9 HARTMANN Veroval BPU22 AViTA BPM63S Pictures Display Image Validation Equivalence ESH 2010 ESH 2002 BHS AAMI Category Arm Type

More information

Validation of the OMRON 705 IT blood pressure measuring device according to the International Protocol of the European Society of Hypertension

Validation of the OMRON 705 IT blood pressure measuring device according to the International Protocol of the European Society of Hypertension Validation of the OMRON 705 IT blood pressure measuring device according to the International Protocol of the European Society of Hypertension M. EL ASSAAD, J. TOPOUCHIAN, G. LABAKI, R. ASMAR L Institut

More information

Device Equivalence Evaluation Form

Device Equivalence Evaluation Form Device Equivalence Evaluation Form Comparison of the HARTMANN Veroval upper arm blood pressure monitor with the AViTA BPM63S Devices Pictures HARTMANN Veroval upper arm blood pressure monitor AViTA BPM63S

More information

Maker Spacelabs Healthcare Manufacturer Spacelabs Healthcare. Brand Spacelabs Model OnTrak

Maker Spacelabs Healthcare Manufacturer Spacelabs Healthcare. Brand Spacelabs Model OnTrak Validation Study Result Form Please complete Section 1 to Section 3 of this form and return it to dabl Educational Trust with copies of the validation plots and a digital photograph of the device used

More information

Validation Study Result Form

Validation Study Result Form Validation Study Result Form Please complete Section 1 to Section 3 of this form and return it to dabl Educational Trust with copies of the validation plots. The requirements for each of these sections

More information

Device Equivalence Evaluation Form

Device Equivalence Evaluation Form Device Equivalence Evaluation Form Comparison of the HARTMANN Veroval wrist blood pressure monitor with the AViTA BPM15S Devices HARTMANN Veroval wrist blood pressure monitor AViTA BPM15S Pictures Display

More information

Declaration of Equivalence Form

Declaration of Equivalence Form Declaration of Equivalence Form DECLARATION OF BLOOD PRESSURE MEASURING DEVICE EQUIVALENCE 2013 SECTION A - Please complete all items. I Bill Huang,, Name of a Company Director A SIGNED COPY WILL BE POSTED

More information

Device Equivalence Evaluation Form

Device Equivalence Evaluation Form Comparison of the HARTMANN Veroval BPW22 with the AViTA BPM15S Devices Item 9 HARTMANN Veroval BPW22 AViTA BPM15S Pictures Display Image Validation Equivalence ESH 2010 ESH 2002 BHS AAMI Category Wrist

More information

a Medical Physics Department, Guy s & St Thomas NHS Foundation Trust and b King s College School of Medicine, St Thomas Campus, London, UK

a Medical Physics Department, Guy s & St Thomas NHS Foundation Trust and b King s College School of Medicine, St Thomas Campus, London, UK Devices and technology 27 Validation of the Omron 705IT (HEM-759-E) oscillometric blood pressure monitoring device according to the British Hypertension Society protocol Andrew Coleman a, Paul Freeman

More information

Device Equivalence Evaluation Form

Device Equivalence Evaluation Form Comparison of the SAFETY PRONTEX INTEGRA (Nissei DS-B33-03) with the Nissei DSK-1011 Devices Item 9 SAFETY PRONTEX INTEGRA (Nissei DS-B33-03) Nissei DSK-1011 Pictures Display Image Validation ESH IP2010

More information

Validation of the SEJOY BP-1307 upper arm blood pressure monitor for home. blood pressure monitoring according to the European Society of Hypertension

Validation of the SEJOY BP-1307 upper arm blood pressure monitor for home. blood pressure monitoring according to the European Society of Hypertension Validation of the SEJOY BP-1307 upper arm blood pressure monitor for home blood pressure monitoring according to the European Society of Hypertension International Protocol revision 2010 Short title: Validation

More information

Validation Study Registration Form

Validation Study Registration Form TrUSt Validation Study Registration Form This form should be completed by the manufacturer or on behalf of the manufacturer. Study Investigator Details Name Address Mrs.Annemarie de Greef and Professor

More information

Device Equivalence Evaluation Form

Device Equivalence Evaluation Form Comparison of the Microlife BP A150 AFIB with the Microlife BP A100 Plus and Microlife BP A100 Device Equivalence Evaluation Form Devices Microlife BP A150 AFIB 9 Microlife BP A100 Plus 9 Microlife BP

More information

1. Department of Gynecology and Obstetrics, St. Joseph's Hospital Berlin Tempelhof, Germany

1. Department of Gynecology and Obstetrics, St. Joseph's Hospital Berlin Tempelhof, Germany Page 1 of 9 Validation of the TONOPORT VI ambulatory blood pressure monitor, according to the European Society of Hypertension International Protocol revision 2010 Michael Abou-Dakn 1, Cornelius Döhmen

More information

STATE OF THE ART BP ASSESSMENT

STATE OF THE ART BP ASSESSMENT STATE OF THE ART BP ASSESSMENT PROFESSOR MOLECULAR PHARMACOLOGY CONWAY INSTITUE UNIVERSITY COLLEGE DUBLIN CO-CHAIRMAN BLOOD PRESCSURE MANAGEMENT IN LOW RESOURCE SETTINGS CENTRE FOR INTERNATIONAL HUMANITARIAN

More information

Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic

Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic Supplementary Information The title of the manuscript Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic stroke Xin-Wei He 1, Wei-Ling Li 1, Cai Li

More information

DR JIRAR TOPOUCHIAN PROF PAROUNAK ZELVEIAN PROF ROLAND ASMAR. September 8 th, Principal Investigator and Study Chair:

DR JIRAR TOPOUCHIAN PROF PAROUNAK ZELVEIAN PROF ROLAND ASMAR. September 8 th, Principal Investigator and Study Chair: Page 1 of 10 Validation of the automatic blood pressure measurements device, the OMRON EVOLV (HEM- 7600 T-E) in Pregnancy according to the Modified European Society of Hypertension International Protocol

More information

Comparison of the Microlife A6 PC (BP3GU1-8Y) with the Microlife BP3BT0-A and Microlife BP A100 Plus

Comparison of the Microlife A6 PC (BP3GU1-8Y) with the Microlife BP3BT0-A and Microlife BP A100 Plus Comparison of the Microlife A6 PC (BP3GU1-8Y) with the Microlife BP3BT0-A and Microlife BP A100 Plus Devices Microlife A6 PC (BP3GU1-8Y) 9 BP3BT0-A 9 Microlife BP A100 Plus 9 Image 10 10 10 Validation

More information

Copyright Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.

Copyright Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. Devices and technology 261 Validation of the ROSSMAX blood pressure measuring monitor according to the European Society of Hypertension International Protocol for Validation of Blood Pressure Measuring

More information

BackBeat Cardiac Neuromodulation Therapy (CNT) for Immediate, Substantial and Sustained Lowering of Blood Pressure. Daniel Burkhoff MD PhD

BackBeat Cardiac Neuromodulation Therapy (CNT) for Immediate, Substantial and Sustained Lowering of Blood Pressure. Daniel Burkhoff MD PhD BackBeat Cardiac Neuromodulation Therapy (CNT) for Immediate, Substantial and Sustained Lowering of Blood Pressure Daniel Burkhoff MD PhD Director Heart Failure, Hemodynamics and Mechanical Support Research

More information

Comparison of the Microlife A2 Basic (BP3GQ1-3P) with the Microlife BP3BT0-A and Microlife BP A100 Plus

Comparison of the Microlife A2 Basic (BP3GQ1-3P) with the Microlife BP3BT0-A and Microlife BP A100 Plus Comparison of the Microlife A2 Basic (BP3GQ1-3P) with the Microlife BP3BT0-A and Microlife BP A100 Plus Devices Microlife A2 Basic (BP3GQ1-3P) 9 BP3BT0-A 9 Microlife BP A100 Plus 9 Image 10 10 10 Validation

More information

Methods DEVICES AND TECHNOLOGY

Methods DEVICES AND TECHNOLOGY DEVICES AND TECHNOLOGY Validation of the Omron HEM-907 device for blood pressure measurement Mohamed A. El Assaad, Jirar A. Topouchian, Bernadette M. Darné and Roland G. Asmar Background The aim of this

More information

SYNOPSIS. Publications No publications at the time of writing this report.

SYNOPSIS. Publications No publications at the time of writing this report. Drug product: TOPROL-XL Drug substance(s): Metoprolol succinate Study code: D4020C00033 (307A) Date: 8 February 2006 SYNOPSIS Dose Ranging, Safety and Tolerability of TOPROL-XL (metoprolol succinate) Extended-release

More information

Epidemiologic Measure of Association

Epidemiologic Measure of Association Measures of Disease Occurrence: Epidemiologic Measure of Association Basic Concepts Confidence Interval for population characteristic: Disease Exposure Present Absent Total Yes A B N 1 = A+B No C D N 2

More information

Reference Values and Simplified Methods for Interpretation of Blood Pressure in Children and Adolescents

Reference Values and Simplified Methods for Interpretation of Blood Pressure in Children and Adolescents Reference Values and Simplified Methods for Interpretation of Blood Pressure in Children and Adolescents Simonetti G.D. Istituto Pediatrico della Svizzera Italiana Ente Ospedaliero Cantonale e Università

More information

Appendix. Supplementary figures and tables

Appendix. Supplementary figures and tables This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Appendix. Supplementary figures and tables Figure A1. Flowchart describing patient

More information

Adherence to Hypertension Visit Protocol Description: % of patients with HTN who are being monitored through follow up visits according to guidelines, based on "days since last BP", which looks back from

More information

a Centre de Médecine Cardiovasculaire, Paris, France, b Lebanese Hospital and Received 7 June 2009 Revised 15 September 2009 Accepted 9 October 2009

a Centre de Médecine Cardiovasculaire, Paris, France, b Lebanese Hospital and Received 7 June 2009 Revised 15 September 2009 Accepted 9 October 2009 42 Original article Validation of three professional devices measuring office blood pressure according to three different methods: the Omron BP, the Omron HBP T and the Pic Indolor Professional Roland

More information

2014 Evidence-Based HTN Guideline: Preliminary Data from AMGA s Anceta Collaborative

2014 Evidence-Based HTN Guideline: Preliminary Data from AMGA s Anceta Collaborative 2014 Evidence-Based HTN Guideline: Preliminary Data from AMGA s Anceta Collaborative February 2014 Patient Population Measure spec for MU/PD generally follows NQF 0018 (used for HEDIS, PQRS, and MU) 1.6

More information

ADVANCE post trial ObservatioNal Study

ADVANCE post trial ObservatioNal Study Hot Topics in Diabetes 50 th EASD, Vienna 2014 ADVANCE post trial ObservatioNal Study Sophia Zoungas The George Institute The University of Sydney Rationale and Study Design Sophia Zoungas The George Institute

More information

Validation study of the Dinamap ProCare 200 upper arm blood pressure monitor in children and adolescents

Validation study of the Dinamap ProCare 200 upper arm blood pressure monitor in children and adolescents Original article http://dx.doi.org/10.3345/kjp.2011.54.11.463 Korean J Pediatr 2011;54(11):463-469 Validation study of the Dinamap ProCare 200 upper arm blood pressure monitor in children and adolescents

More information

and bias, which are known to be present in self-home and in professional office BP measurements taken using the auscultatory technique [7].

and bias, which are known to be present in self-home and in professional office BP measurements taken using the auscultatory technique [7]. Devices and technology 37 Validation of the A&D UM-11 professional hybrid device for office blood pressure measurement according to the International Protocol George S. Stergiou, Periklis P. Giovas, Charilaos

More information

Copyright Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.

Copyright Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. Devices and technology 57 Comparison of wrist-type and arm-type 24-h blood pressure monitoring devices for ambulatory use Takahiro Komori a, Kazuo Eguchi a, Satoshi Hoshide a, Bryan Williams b and Kazuomi

More information

BLOOD PRESSURE MEASUREMENT HOME BASED OR OFFICE BP MONITORING WHICH, HOW AND WHEN?

BLOOD PRESSURE MEASUREMENT HOME BASED OR OFFICE BP MONITORING WHICH, HOW AND WHEN? BLOOD PRESSURE MEASUREMENT HOME BASED OR OFFICE BP MONITORING WHICH, HOW AND WHEN? DECLARATION OF INTEREST Medical Director and Chairman, Advisory Board dabl Ltd., Dublin, Ireland. BLOOD PRESSURE MEASUREMENT

More information

Quality ID #122: Adult Kidney Disease: Blood Pressure Management National Quality Strategy Domain: Effective Clinical Care

Quality ID #122: Adult Kidney Disease: Blood Pressure Management National Quality Strategy Domain: Effective Clinical Care Quality ID #122: Adult Kidney Disease: Blood Pressure Management National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Intermediate

More information

HCHS/SOL Submission Instructions for Manuscripts or Publications

HCHS/SOL Submission Instructions for Manuscripts or Publications HCHS/SOL Submission Instructions for Manuscripts or Publications What is this? This is an example of an ideal submission of manuscripts or publications on the HCHS/SOL website. This example describes the

More information

Hypertension JNC 8 (2014)

Hypertension JNC 8 (2014) Hypertension JNC 8 (2014) Renewed: February 2018 Updated: February 2015 Comparison of Seventh Joint National Committee (JNC 7) vs. Eighth Joint National Committee (JNC 8) Hypertension Guidelines Methodology

More information

A GUIDE TO OUR NIBP TECHNOLOGY

A GUIDE TO OUR NIBP TECHNOLOGY GE Healthcare THE DINAMAP DIFFERENCE A GUIDE TO OUR NIBP TECHNOLOGY OUR TECHNOLOGICAL ADVANTAGES THE OSCILLOMETRIC METHODOLOGY Oscillometry is the most commonly used means of indirect blood pressure measurement

More information

Hypertension and the SPRINT Trial: Is Lower Better

Hypertension and the SPRINT Trial: Is Lower Better Hypertension and the SPRINT Trial: Is Lower Better 8th Annual Orange County Symposium on Cardiovascular Disease Prevention Saturday, October 8, 2016 Keith C. Norris, MD, PhD, FASN Professor of Medicine,

More information

Depok-Indonesia STEPS Survey 2003

Depok-Indonesia STEPS Survey 2003 The STEPS survey of chronic disease risk factors in Indonesia/Depok was carried out from February 2003 to March 2003. Indonesia/Depok carried out Step 1, Step 2 and Step 3. Socio demographic and behavioural

More information

THE NEW ARMENIAN MEDICAL JOURNAL DISTRIBUTION, AWARENESS, TREATMENT, AND CONTROL OF ARTERIAL HYPERTENSION IN YEREVAN (ARMENIA)

THE NEW ARMENIAN MEDICAL JOURNAL DISTRIBUTION, AWARENESS, TREATMENT, AND CONTROL OF ARTERIAL HYPERTENSION IN YEREVAN (ARMENIA) THE NEW ARMENIAN MEDICAL JOURNAL Vol.5 (2011), Nо 2, p.29-34 DISTRIBUTION, AWARENESS, TREATMENT, AND CONTROL OF ARTERIAL HYPERTENSION IN YEREVAN (ARMENIA) Zelveian P.H. 1, 2, Podosyan G.A. 2 1 Institute

More information

Received 10 April 2008 Revised 23 June 2008 Accepted 24 June 2008

Received 10 April 2008 Revised 23 June 2008 Accepted 24 June 2008 342 Original article Development of an accurate oscillometric blood pressure device for low resource settings Annemarie de Greeff, Hannah Nathan, Nina Stafford, Bing Liu and Andrew H. Shennan Objective

More information

Hypertension Update 2016 AREEF ISHANI, MD MS CHIEF OF MEDICINE MINNEAPOLIS VA MEDICAL CENTER PROFESSOR OF MEDICINE UNIVERSITY OF MINNESOTA

Hypertension Update 2016 AREEF ISHANI, MD MS CHIEF OF MEDICINE MINNEAPOLIS VA MEDICAL CENTER PROFESSOR OF MEDICINE UNIVERSITY OF MINNESOTA Hypertension Update 2016 AREEF ISHANI, MD MS CHIEF OF MEDICINE MINNEAPOLIS VA MEDICAL CENTER PROFESSOR OF MEDICINE UNIVERSITY OF MINNESOTA Case 1 What should be your BP goal for an elderly (> 75 yrs of

More information

KDIGO Controversies Conference on Blood Pressure in CKD

KDIGO Controversies Conference on Blood Pressure in CKD KDIGO Controversies Conference on Blood Pressure in CKD September 7-10, 2017 Edinburgh, Scotland Kidney Disease: Improving Global Outcomes (KDIGO) is an international organization whose mission is to improve

More information

University of Padova, Padua, Italy, and HARVEST Study Group, Italy

University of Padova, Padua, Italy, and HARVEST Study Group, Italy University of Padova, Padua, Italy, and HARVEST Study Group, Italy ISOLATED SYSTOLIC HYPERTENSION IN THE YOUNG DOES NOT IMPLY AN INCREASED RISK OF FUTURE HYPERTENSION NEEDING TREATMENT Mos L, Saladini

More information

Hypertension Guidelines 2017

Hypertension Guidelines 2017 Hypertension Guidelines 2017 (American College of Cardiology and the American Heart Association) In 1977, the 1st comprehensive guideline for detection, evaluation, and management of high BP was published,

More information

New Hypertension Guideline Recommendations for Adults July 7, :45-9:30am

New Hypertension Guideline Recommendations for Adults July 7, :45-9:30am Advances in Cardiovascular Disease 30 th Annual Convention and Reunion UERM-CMAA, Inc. Annual Convention and Scientific Meeting July 5-8, 2018 New Hypertension Guideline Recommendations for Adults July

More information

Blood Pressure Measurement Does it matter where you do it or how often?

Blood Pressure Measurement Does it matter where you do it or how often? Blood Pressure Measurement Does it matter where you do it or how often? James (Jim) M. Wright Coordinating Editor Cochrane Hypertension Group Conflict of Interest First half evidence based, no conflicts.

More information

Copyright Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.

Copyright Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. Devices and technology 16 Validation of two automatic devices for self-measurement of blood pressure according to the International Protocol of the European Society of Hypertension: the Omron M6 (HEM-71-E)

More information

Blood Pressure Acre Surgery Diviash Thakrar

Blood Pressure Acre Surgery Diviash Thakrar Blood Pressure Acre Surgery Diviash Thakrar Why Are We Doing This? 1. Improve education for patients within the practice 2. Allow us use this for general health promotion Raise money for charity 3. Raise

More information

ANTIHYPERTENSIVE DRUG THERAPY IN CONSIDERATION OF CIRCADIAN BLOOD PRESSURE VARIATION*

ANTIHYPERTENSIVE DRUG THERAPY IN CONSIDERATION OF CIRCADIAN BLOOD PRESSURE VARIATION* Progress in Clinical Medicine 1 ANTIHYPERTENSIVE DRUG THERAPY IN CONSIDERATION OF CIRCADIAN BLOOD PRESSURE VARIATION* Keishi ABE** Asian Med. J. 44(2): 83 90, 2001 Abstract: J-MUBA was a large-scale clinical

More information

ABPM screen 300/400 Risk Assessment

ABPM screen 300/400 Risk Assessment ABPM screen 300/400 Risk Assessment Highlights of custo screen400 ABPM 24 hours Synchronized ABPM and Holter ECG recordings in combination with custo guard 3 72 hours for ABPM recordings alone To our knowledge,

More information

SUPPLEMENTARY DATA. Supplementary Table 1. Baseline Patient Characteristics

SUPPLEMENTARY DATA. Supplementary Table 1. Baseline Patient Characteristics Supplementary Table 1. Baseline Patient Characteristics Normally distributed data are presented as mean (±SD), data that were not of a normal distribution are presented as median (ICR). The baseline characteristics

More information

2. Measure a subject's blood pressure and heart rate both at rest and during exercise.

2. Measure a subject's blood pressure and heart rate both at rest and during exercise. Lab Activity 11 The Cardiovascular System Student Learning Objectives After completing this lab, you should be able to: 1. Define, explain and correctly use the key terms. 2. Measure a subject's blood

More information

JNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH

JNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH JNC 8 -Controversies Sagren Naidoo Nephrologist CMJAH Joint National Committee (JNC) Panel appointed by the National Heart, Lung, and Blood Institute (NHLBI) First guidelines (JNC-1) published in 1977

More information

The Use of Alternative Therapies to Lower Blood Pressure in Older African Americans

The Use of Alternative Therapies to Lower Blood Pressure in Older African Americans The Use of Alternative Therapies to Lower Blood Pressure in Older African Americans Cardiovascular (CVD) disease is the leading cause of death in the USA, especially for African Americans, who have higher

More information

T. Suithichaiyakul Cardiomed Chula

T. Suithichaiyakul Cardiomed Chula T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial

More information

Patient is healthy with no chronic disease or significant risk factors [16%].

Patient is healthy with no chronic disease or significant risk factors [16%]. AAFP Risk Level 1 Patient is healthy with no chronic disease or significant risk factors [16%]. Exclude the following chronic problems from active patient list o Depression o Diabetes Type I or Type II

More information

Charles Spencer MD, FRCP Consultant Cardiologist Mid Staffs NHSFT

Charles Spencer MD, FRCP Consultant Cardiologist Mid Staffs NHSFT Charles Spencer MD, FRCP Consultant Cardiologist Mid Staffs NHSFT Key Messages Heart Failure is Common Heart failure is complex Heart Failure is a major issue for the NHS Heart Failure has a worse prognosis

More information

doi: /fampra/cmw053

doi: /fampra/cmw053 doi: 10.1093/fampra/cmw053 Manuscript type Original research Title Comparison of blood pressure measurements on the bare arm, over a sleeve, and over a rolled-up sleeve in the elderly Short title Blood

More information

Optimal blood pressure targets in chronic kidney disease

Optimal blood pressure targets in chronic kidney disease Optimal blood pressure targets in chronic kidney disease Pr. Michel Burnier Service of Nephrology and Hypertension University Hospital Lausanne Switzerland Evidence-Based Guideline for the Management

More information

Antihypertensive Trial Design ALLHAT

Antihypertensive Trial Design ALLHAT 1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes

More information

The introduction of oscillometric automated blood pressure

The introduction of oscillometric automated blood pressure Atrial Fibrillation Impact of Atrial Fibrillation on the Accuracy of Oscillometric Blood Pressure Monitoring Nikolaos Pagonas,* Sven Schmidt,* Jörg Eysel, Friederike Compton, Clemens Hoffmann, Felix Seibert,

More information

Objectives. Describe results and implications of recent landmark hypertension trials

Objectives. Describe results and implications of recent landmark hypertension trials Hypertension Update Daniel Schwartz, MD Assistant Professor of Medicine Associate Medical Director of Heart Transplantation Temple University School of Medicine Disclosures I currently have no relationships

More information

Zhengtao Liu 1,2,3*, Shuping Que 4*, Lin Zhou 1,2,3 Author affiliation:

Zhengtao Liu 1,2,3*, Shuping Que 4*, Lin Zhou 1,2,3 Author affiliation: Dose-response Relationship of Serum Uric Acid with Metabolic Syndrome and Non-alcoholic Fatty Liver Disease Incidence: AMeta-analysis of Prospective Studies Zhengtao Liu 1,2,3*, Shuping Que 4*, Lin Zhou

More information

Statin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography

Statin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography Statin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography Hyo Eun Park 1, Eun-Ju Chun 2, Sang-Il Choi 2, Soyeon Ahn 2, Hyung-Kwan Kim 3,

More information

Home Blood Pressure Log

Home Blood Pressure Log Home Blood Pressure Log 2 You or your health care professional may want to monitor your blood pressure at home twice a day for a week or more before appointments to accurately confirm your average blood

More information

Seasonal variation in blood pressure and its relationship with outdoor air temperature in 10 diverse regions of China: the China Kadoorie Biobank

Seasonal variation in blood pressure and its relationship with outdoor air temperature in 10 diverse regions of China: the China Kadoorie Biobank Seasonal variation in blood pressure and its relationship with outdoor air temperature in diverse regions of China: the China Kadoorie Biobank SUPPLEMENTAL MATERIAL 1 Tables etable 1: Seasonal mean outdoor

More information

New Hypertension Guidelines: Why the change? Neil Brummond, M.D. Avera Medical Group Internal Medicine Sioux Falls, SD

New Hypertension Guidelines: Why the change? Neil Brummond, M.D. Avera Medical Group Internal Medicine Sioux Falls, SD New Hypertension Guidelines: Why the change? Neil Brummond, M.D. Avera Medical Group Internal Medicine Sioux Falls, SD None Disclosures Objectives Understand trend in blood pressure clinical practice guidelines

More information

Critical Review Form Therapy

Critical Review Form Therapy Critical Review Form Therapy Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion Lancet 1993; 341:501-511 Objective: To determine

More information

Research Article Prevalence, Awareness, Treatment, and Control of Hypertension in Romania: Results of the SEPHAR Study

Research Article Prevalence, Awareness, Treatment, and Control of Hypertension in Romania: Results of the SEPHAR Study SAGE-Hindawi Access to Research International Journal of Hypertension Volume 2010, Article ID 970694, 6 pages doi:10.4061/2010/970694 Research Article Prevalence, Awareness, Treatment, and Control of Hypertension

More information

Blood Pressure Measurement in SPRINT

Blood Pressure Measurement in SPRINT Blood Pressure Measurement in SPRINT Karen C. Johnson, MD, MPH, FAHA Vice Chair, SPRINT Steering Committee University of Tennessee Health Science Center, Department of Preventive Medicine For the SPRINT

More information

Does masked hypertension exist in healthy volunteers and apparently well-controlled hypertensive patients?

Does masked hypertension exist in healthy volunteers and apparently well-controlled hypertensive patients? O R I G I N A L A R T I C L E Does masked hypertension exist in healthy volunteers and apparently well-controlled hypertensive patients? I. Aksoy, J. Deinum, J.W.M. Lenders, Th. Thien *# Department of

More information

Vital Signs. Vital Signs. Pulse. Temperature. Respiration. Blood Pressure

Vital Signs. Vital Signs. Pulse. Temperature. Respiration. Blood Pressure Vital Signs Jarvis, Chapter 9 Vital Signs Classic Vital Signs TPR/BP Temperature Pulse Respirations Blood Pressure Additional Vital Signs Height Weight BMI (Kg/m2) or (702Xlbs/in2) Supine, orthostatic

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis

More information

Implications of Drug-related Increases in Blood Pressure

Implications of Drug-related Increases in Blood Pressure Implications of Drug-related Increases in Blood Pressure Preston M. Dunnmon, MD, FACP, FACC Division of Cardiovascular and Renal Products US Food and Drug Administration July 18, 2012 Disclaimer The findings

More information

Individual Study Table Referring to Item of the Submission: Volume: Page:

Individual Study Table Referring to Item of the Submission: Volume: Page: 2.0 Synopsis Name of Company: Abbott Laboratories Name of Study Drug: Meridia Name of Active Ingredient: Sibutramine hydrochloride monohydrate Individual Study Table Referring to Item of the Submission:

More information

Systolic Blood Pressure Intervention Trial (SPRINT)

Systolic Blood Pressure Intervention Trial (SPRINT) 09:30-09:50 2016.4.15 Systolic Blood Pressure Intervention Trial (SPRINT) IN A NEPHROLOGIST S VIEW Sejoong Kim Seoul National University Bundang Hospital Current guidelines for BP control Lowering BP

More information

IRBES_R_04320 Generic drug name: Irbesartan + amlodipine Date: Study Code: 31 active centers: 20 in Korea, 7 in India and 4 in Philippines.

IRBES_R_04320 Generic drug name: Irbesartan + amlodipine Date: Study Code: 31 active centers: 20 in Korea, 7 in India and 4 in Philippines. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinicalTrials.gov

More information

High intensity exercise improves cardiac structure and function and reduces liver fat in adults with Type 2 diabetes

High intensity exercise improves cardiac structure and function and reduces liver fat in adults with Type 2 diabetes High intensity exercise improves cardiac structure and function and reduces liver fat in adults with Type 2 diabetes Sophie Cassidy, s.cassidy@ncl.ac.uk 1) Concentric remodelling 1.2 * Eccentricity ratio

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

The role of physical activity in the prevention and management of hypertension and obesity

The role of physical activity in the prevention and management of hypertension and obesity The 1 st World Congress on Controversies in Obesity, Diabetes and Hypertension (CODHy) Berlin, October 26-29 2005 The role of physical activity in the prevention and management of hypertension and obesity

More information

Using the New Hypertension Guidelines

Using the New Hypertension Guidelines Using the New Hypertension Guidelines Kamal Henderson, MD Department of Cardiology, Preventive Medicine, University of North Carolina School of Medicine Kotchen TA. Historical trends and milestones in

More information

DEVICES AND TECHNOLOGY

DEVICES AND TECHNOLOGY DEVICES AND TECHNOLOGY Validation of a new algorithm for the BPM-100 electronic oscillometric office blood pressure monitor James M. Wright ab, Gurdial S. Mattu a, Thomas L. Perry Jr ab, Mark E. Gelfer

More information

Hypertension targets in the elderly. Sarah McCracken Consultant Geriatrician North Bristol NHS Trust September 2016

Hypertension targets in the elderly. Sarah McCracken Consultant Geriatrician North Bristol NHS Trust September 2016 Hypertension targets in the elderly Sarah McCracken Consultant Geriatrician North Bristol NHS Trust September 2016 NICE (2011) Aim for a target clinic blood pressure below 150/90 mmhg in people aged 80

More information

Blood Pressure Targets in Diabetes

Blood Pressure Targets in Diabetes Stockholm, 29 th August 2010 ESC Meeting Blood Pressure Targets in Diabetes Peter M Nilsson, MD, PhD Department of Clinical Sciences University Hospital, Malmö Sweden Studies on BP in DM2 ADVANCE RCT (Lancet

More information

Design and analysis of clinical trials

Design and analysis of clinical trials Design and analysis of clinical trials Lecture 3 1.Basic Design Considerations 2.Sample Size determinationa 3.Randomization 2018-01-31 Previous Lectures Definition of a clinical trial The drug development

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Lewington S, Lacey B, Clarke R, et al; China Kadoorie Biobank Consortium. The burden of hypertension and associated risk for cardiovascular mortality in China. JAMA Intern

More information

Use and Interpretation of Home Blood Pressure Monitoring

Use and Interpretation of Home Blood Pressure Monitoring Use and Interpretation of Home Blood Pressure Monitoring BLOOD PRESSURE in year 2015 PARAMETERS TODAY Gianfranco Parati University of Milano-Bicocca & Ospedale S.Luca, IRCCS, Istituto Auxologico Italiano

More information

Theoretical and practical questions in the evaluation of arterial function Miklós Illyés MD. Ph.D.

Theoretical and practical questions in the evaluation of arterial function Miklós Illyés MD. Ph.D. Theoretical and practical questions in the evaluation of arterial function Miklós Illyés MD. Ph.D. TensioMed Arterial Stiffness Centre, Budapest Heart Institute, Faculty of Medicine, University of Pécs

More information

Masked Hypertension and Aortic Coarctation: Impact on Ventricular Function and Morphology

Masked Hypertension and Aortic Coarctation: Impact on Ventricular Function and Morphology Masked Hypertension and Aortic Coarctation: Impact on Ventricular Function and Morphology Giovanni Di Salvo MD, PhD, MMSc, FESC BACKGROUND MASKED HYPERTENSION Masked hypertension (MH) consists of an elevated

More information

HYPERTENSION AND HEART FAILURE

HYPERTENSION AND HEART FAILURE HYPERTENSION AND HEART FAILURE Kenya Cardiac Society Symposium Feb 2017 Dr Jeilan Mohamed No conflict of interests . Geoffrey, 45 yr old hypertensive office worker male from Nairobi, has just watched his

More information

Revision of 10/27/2017 Form #280 Page 1 of 12 PVDOMICS STUDY Clinical Center Right Heart Catheterization (RHC) Results Form #280

Revision of 10/27/2017 Form #280 Page 1 of 12 PVDOMICS STUDY Clinical Center Right Heart Catheterization (RHC) Results Form #280 Revision of 10/27/2017 Form #280 Page 1 of 12 PVDOMICS STUDY Clinical Center Right Heart Catheterization (RHC) Results Form #280 Instructions: Review PVDOMICS MOP Chapter 100 prior to completing right

More information

Advances in Peritoneal Dialysis, Vol. 34, 2018

Advances in Peritoneal Dialysis, Vol. 34, 2018 Advances in Peritoneal Dialysis, Vol. 34, 2018 Vasilios Vaios, 1 Panagiotis I. Georgianos, 1 Maria I. Pikilidou, 1 Theodoros Eleftheriadis, 2 Sotirios Zarogiannis, 3 Aikaterini Papagianni, 4 Pantelis E.

More information

Ambulatory BP Monitoring: Getting the Diagnosis of Hypertension Right. Anthony J. Viera, MD, MPH, FAHA Professor and Chair

Ambulatory BP Monitoring: Getting the Diagnosis of Hypertension Right. Anthony J. Viera, MD, MPH, FAHA Professor and Chair Ambulatory BP Monitoring: Getting the Diagnosis of Hypertension Right Anthony J. Viera, MD, MPH, FAHA Professor and Chair Objectives Review limitations of office BP in making a correct diagnosis of hypertension

More information

Special Lecture 10/28/2012

Special Lecture 10/28/2012 Special Lecture 10/28/2012 HYPERTENSION Dr. HN Mayrovitz Special Lecture 10/28/2012 Arterial Blood Pressure (ABP) - Definitions ABP Review Indirect Oscillographic Method Resistance (R), Compliance (C)

More information

Interested parties (organisations or individuals) that commented on the draft document as released for consultation.

Interested parties (organisations or individuals) that commented on the draft document as released for consultation. 23 June 2016 EMA/CHMP/345847/2015 Committee for Medicinal products for Human Use Overview of comments received on ''Guideline on clinical investigation of medicinal products in the treatment of hypertension'

More information